Adaptimmune to Present at the Cowen and Company 37th Annual Health Care Conference

Print
| Source: Adaptimmune Therapeutics plc

PHILADELPHIA and OXFORD, United Kingdom, March 02, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble, Adaptimmune’s Chief Executive Officer, will present at the Cowen and Company 37th Annual Health Care Conference on Tuesday March 7, 2017 at 10:40-11:10 AM EST (3:40-4:10 PM GMT). The conference is being held at the Boston Marriott Copley Plaza. Adaptimmune’s presentation will be webcast live for investors through the investor section of www.adaptimmune.com and available for a period of 30 days following the conference.

About Adaptimmune

Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products. The Company’s unique SPEAR® (Specific Peptide Enhanced Affinity Receptor) T‑cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. Adaptimmune has a number of proprietary clinical programs, and is also developing its NY-ESO SPEAR T-cell program under a strategic collaboration and licensing agreement with GlaxoSmithKline. The Company is located in Philadelphia, USA and Oxfordshire, U.K. For more information, please visit http://www.adaptimmune.com

Adaptimmune Contacts 

Investor Relations
Will Roberts
T:  (215) 825-9306  
E: will.roberts@adaptimmune.com

Juli P. Miller, Ph.D.
T: (215) 825-9310
E: juli.miller@adaptimmune.com

Media Relations
Margaret Henry 
T: +44 (0)1235 430036 
Mobile: +44 (0)7710 304249 
E: margaret.henry@adaptimmune.com